Skip to main content
Premium Trial:

Request an Annual Quote

Stratos Biosystems Develops Protein Chip for Cancer Biomarker Research; Looks for Collaborators

NEW YORK (GenomeWeb News) — Stratos Biosystems said Monday that it has completed pilot production capability for a new protein chip technology that could be used in biomarker-discovery programs for early cancer detection.
Stratos said its EC-Affinity chips for MALDI mass spectrometry are designed to give researchers a high-throughput affinity chromatography tool that is based on a new “self-assembling surface chemistry.”
The biochip technology will be used to detect “extremely rare proteins,” Stratos said, and will address what it calls a “major problem of lack of capacity and functionality” in detecting cancer-related proteins.
The company said it is now actively seeking new collaborators and partners.
Stratos has been funded by numerous groups and individuals, including its chief scientist Mark Stolowitz. In 2001 Stolowitz left Bothell, Wash., protein chip technology company Prolinx, where he was chief technology officer, to become vice president of biochip technologies at Lumicyte.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.